Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have developed a novel RNA-based therapy that could transform treatment for metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic fatty liver disease (NAFLD), which affects approximately 25% of people worldwide, and up to 40% of adults in Singapore.